Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

EPACT II: Project and Methods

Juillerat P.a · Froehlich F.a, b · Felley C.a · Pittet V.c · Mottet C.a · Gonvers J.-J.a · Michetti P.a · Vader J.-P.c

Author affiliations

aDivision of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, bGastrointestinal Department, University of Basle, Basle, and cHealthcare Evaluation Unit, Institute of Social and Preventive Medicine, University of Lausanne, Lausanne, Switzerland

Related Articles for ""

Digestion 2007;76:84–91

Do you have an account?

Login Information





Contact Information












By signing up for MyKarger you will automatically participate in our year-End raffle.
If you Then Do Not wish To participate, please uncheck the following box.

Yes, I wish To participate In the year-End raffle And Get the chance To win some Of our most interesting books, And other attractive prizes.


I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information












By signing up for MyKarger you will automatically participate in our year-End raffle.
If you Then Do Not wish To participate, please uncheck the following box.

Yes, I wish To participate In the year-End raffle And Get the chance To win some Of our most interesting books, And other attractive prizes.


I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Paper

Published online: February 07, 2008
Issue release date: February 2008

Number of Print Pages: 8
Number of Figures: 1
Number of Tables: 5

ISSN: 0012-2823 (Print)
eISSN: 1421-9867 (Online)

For additional information: https://www.karger.com/DIG

Abstract

Building on the first European Panel on the Appropriateness of Crohn’s Disease Treatment (EPACT I) which was held in Lausanne at the beginning of March 2004, a new panel will be convened in Switzerland (EPACT II, November to December 2007) to update this work. A combined evidence- and panel-based method (RAND) will be applied to assess the appropriateness of therapy for Crohn’s disease (CD). In preparation for the meeting of experts, reviews of evidence-based literature were prepared for major clinical presentations of CD. During the meeting, an international multidis- ciplinary panel that includes gastroenterologists, surgeons and general practitioners weigh the strength of evidence and apply their clinical experience when assessing the appropriateness of therapy for 569 specific indications (clinical scenarios). This chapter describes in detail the process of updating the literature review and the systematic approach of the RAND Appropriateness Method used during the expert panel meeting.

© 2008 S. Karger AG, Basel


References

  1. Bernstein SJ, Hilborne LH, Leape LL, Fiske ME, Park RE, Kamberg CJ, Brook RH: The appropriateness of use of coronary angiography in New York State. JAMA 1993;269:766–769.
  2. Park RE, Fink A, Brook RH, Chassin MR, Kahn KL, Merrick NJ, Kosecoff J, Solomon DH: Physician ratings of appropriate indications for six medical and surgical procedures. Am J Public Health 1986;76:766–772.
  3. Shekelle PG, Kahan JP, Bernstein SJ, Leape LL, Kamberg CJ, Park RE: The reproducibility of a method to identify the overuse and underuse of medical procedures. N Engl J Med 1998;338:1888–1895.
  4. Vader JP, Porchet F, Larequi-Lauber T, Dubois RW, Burnand B: Appropriateness of surgery for sciatica: reliability of guidelines from expert panels. Spine 2000;25:1831–1836.
  5. Naylor CD: What is appropriate care? N Engl J Med 1998;338:1918–1920.
  6. Brook RH, Chassin MR, Fink A, Solomon DH, Kosecoff J, Park RE: A method for the detailed assessment of the appropriateness of medical technologies. Int J Technol Assess Health Care 1986;2:53–63.
  7. Bochud M, Burnand B, Froehlich F, Dubois RW, Vader JP, Gonvers JJ: 13. Appropriateness of colonoscopy: surveillance after curative resection of colorectal cancer. Endoscopy 1999;31:664–672.
  8. Bochud M, Burnand B, Froehlich F, Dubois RW, Vader JP, Gonvers JJ: 12. Appropriateness of colonoscopy: surveillance after polypectomy. Endoscopy 1999;31:654–663.
  9. Bochud M, Gonvers JJ, Vader JP, Dubois RW, Burnand B, Froehlich F: 3. Appropriateness of gastroscopy: Barrett’s esophagus. Endoscopy 1999;31:604–610.
  10. Bochud M, Gonvers JJ, Vader JP, Dubois RW, Burnand B, Froehlich F: 2. Appropriateness of gastroscopy: gastro-esophageal reflux disease. Endoscopy 1999;31:596–603.
  11. Burnand B, Bochud M, Froehlich F, Dubois RW, Vader JP, Gonvers JJ: 14. Appropriateness of colonoscopy: screening for colorectal cancer in asymptomatic individuals. Endoscopy 1999;31:673–683.
  12. De Bosset V, Gonvers JJ, Burnand B, Dubois RW, Vader JP, Froehlich F: 7. Appropriateness of colonoscopy: iron-deficiency anemia. Endoscopy 1999;31:627–630.
  13. de Bosset V, Gonvers JJ, Froehlich F, Dubois RW, Burnand B, Vader JP: 5. Appropriateness of gastroscopy: bleeding and dysphagia. Endoscopy 1999;31:615–622.
  14. De Bosset V, Gonvers JJ, Vader JP, Dubois RW, Burnand B, Froehlich F: 9. Appropriateness of colonoscopy: lower abdominal pain or constipation. Endoscopy 1999;31:637–640.
  15. Froehlich F, Bochud M, Gonvers JJ, Dubois RW, Vader JP, Wietlisbach V, Burnand B: 1. Appropriateness of gastroscopy: dyspepsia. Endoscopy 1999;31:579–595.
  16. Froehlich F, Gonvers JJ, Vader JP, Dubois RW, Burnand B: Appropriateness of gastrointestinal endoscopy: risk of complications. Endoscopy 1999;31:684–686.
  17. Froehlich F, Larequi-Lauber T, Gonvers JJ, Dubois RW, Burnand B, Vader JP: 11. Appropriateness of colonoscopy: inflammatory bowel disease. Endoscopy 1999;31:647–653.
  18. Gonvers JJ, Bochud M, Burnand B, Froehlich F, Dubois RW, Vader JP: 10. Appropriateness of colonoscopy: diarrhea. Endoscopy 1999;31:641–646.
  19. Gonvers JJ, De Bosset V, Froehlich F, Dubois RW, Burnand B, Vader JP: 8. Appropriateness of colonoscopy: hematochezia. Endoscopy 1999;31:631–636.
  20. Gonvers JJ, De Bosset V, Vader JP, Dubois RW, Burnand B, Froehlich F: 6. Appropriateness of gastroscopy: risk factors for gastric cancer. Endoscopy 1999;31:623–626.
  21. Vader JP, Burnand B, Froehlich F, Dubois RW, Bochud M, Gonvers JJ: The European Panel on Appropriateness of Gastrointestinal Endoscopy (EPAGE): project and methods. Endoscopy 1999;31:572–578.
  22. Vader JP, Froehlich F, Dubois RW, Beglinger C, Wietlisbach V, Pittet V, Ebel N, Gonvers JJ, Burnand B: European Panel on the Appropriateness of Gastrointestinal Endoscopy (EPAGE): conclusion and WWW site. Endoscopy 1999;31:687–694.
  23. Vader JP, Larequi-Lauber T, Froehlich F, Burnand B, Dubois RW, Gonvers JJ: 4. Appropriateness of gastroscopy: atypical chest pain. Endoscopy 1999;31:611–614.
  24. European Crohn’s and Colitis Organization, http://www.ecco-ibd.org/.
  25. Caprilli R, Michetti P: The European Panel on the Appropriateness of Crohn’s Disease Therapy. Digestion 2005;71:6–7.
  26. Felley C, Mottet C, Juillerat P, Froehlich F, Burnand B, Vader JP, Michetti P, Gonvers JJ: Fistulizing Crohn’s disease. Digestion 2005;71:26–28.
  27. Froehlich F, Juillerat P, Felley C, Mottet C, Vader JP, Burnand B, Michetti P, Gonvers JJ: Treatment of postoperative Crohn’s disease. Digestion 2005;71:49–53.
  28. Froehlich F, Juillerat P, Mottet C, Felley C, Vader JP, Burnand B, Gonvers JJ, Michetti P: Obstructive fibrostenotic Crohn’s disease. Digestion 2005;71:29–30.
  29. Gonvers JJ, Juillerat P, Mottet C, Felley C, Burnand B, Vader JP, Michetti P, Froehlich F: Maintenance of remission in Crohn’s disease. Digestion 2005;71:41–48.
  30. Juillerat P, Felley C, Mottet C, Froehlich F, Vader JP, Burnand B, Gonvers JJ, Michetti P: Drug safety in the treatment of Crohn’s disease. Digestion 2005;71:8–12.
  31. Juillerat P, Mottet C, Froehlich F, Felley C, Vader JP, Burnand B, Gonvers JJ, Michetti P: Extraintestinal manifestations of Crohn’s disease. Digestion 2005;71:31–36.
  32. Michetti P, Juillerat P, Mottet C, Gonvers JJ, Burnand B, Vader JP, Froehlich F, Felley C: Therapy of mild to moderate luminal Crohn’s disease. Digestion 2005;71:13–18.
  33. Michetti P, Mottet C, Juillerat P, Felley C, Vader JP, Burnand B, Gonvers JJ, Froehlich F: Severe and steroid-resistant Crohn’s disease. Digestion 2005;71:19–25.
  34. Mottet C, Juillerat P, Gonvers JJ, Froehlich F, Burnand B, Vader JP, Michetti P, Felley C: Pregnancy and Crohn’s disease. Digestion 2005;71:54–61.
  35. Mottet C, Juillerat P, Gonvers JJ, Michetti P, Burnand B, Vader JP, Felley C, Froehlich F: Treatment of gastroduodenal Crohn’s disease. Digestion 2005;71:37–40.
  36. Center for Evidence Based Medicine, http://www.cebm.net/
  37. Medscape.com, http://www.medscape.com
  38. Translating Research Into Practice (TRIP) Database, www.tripdatabase.com/
  39. Web of Science, ISI Web of knowledge, http://portal.isiknowledge.com
  40. Elsevier Science Direct, http://www.elsevier.com
  41. Database of Abstracts of Reviews of Effectiveness, http://www.crd.york.ac.uk/crdweb/
  42. Ingentaconnect on-line publishing service, http://www.ingentaconnect.com/
  43. Froehlich F, Michetti P, Juillerat P, Felley C, Mottet C, Wietlisbach V, Pittet V, Dubois R, Vader JP, Burnand B, Gonvers JJ: Appropriateness of treatment for maintenance of medically- or surgically-induced remission in Crohn’s disease. A Multidisciplinary European Expert Panel (EPACT). Gastroenterology 2005;128:A307–A308.
    External Resources
  44. Juillerat P, Burnand B, Felley C, Froehlich F, Mottet C, Wietlisbach V, Pittet V, Dubois R, Michetti P, Gonvers JJ, Vader JP: How should we treat complicated Crohn’s disease? A multidisciplinary European Expert Panel (EPACT). Gastroenterology 2005;128:A422– A423.
    External Resources
  45. Mottet C, Froehlich F, Juillerat P, Burnard B, Vader JP, Felley C, Pittet V, Wietlisbach V, Dubois R, Gonvers JJ, Michetti P: Which treatments are appropriate for acute or steroid-refractory/dependent Crohn’s disease? A multidisciplinary European Expert Panel (EPACT). Gastroenterology 2005;128:A312.
    External Resources
  46. Mottet C, Juillerat P, Felley C, Wietlisbach V, Pittet V, Gonvers JJ, Dubois RW, Vader JP, Burnand B, Froehlich F, Michetti P: Crohn’s disease in pregnant women and nursing mothers: which drugs are safe? A multidisciplinary European Expert Panel (EPACT). Gastroenterology 2006;130:A203–A204.
    External Resources
  47. Vader JP, Froehlich F, Juillerat P, Burnand B, Felley C, Gonvers JJ, Mottet C, Pittet V, Dubois RW, Wietlisbach V, Michetti P: Appropriate treatment for Crohn’s disease: methodology and summary results of a mul- tidisciplinary international expert panel approach – EPACT. Digestion 2006;73:237–248.
  48. Guessous I, Juillerat P, Pittet V, Froehlich F, Burnand B, Mottet C, Felley C, Michetti P, Vader JP: Evaluating appropriateness of treatment for Crohn’s disease: feasibility of an explicit approach. Digestion 2007;75:46–52.
  49. Juillerat P, Pittet V, Mottet C, Felley C, Wietlisbach V, Gonvers JJ, Dubois RW, Vader JP, Burnard B, Froehlich F, Wolters F, Stockbruegger R, Michetti P: Appropriateness of initial treatment for mild-to-moderate luminal Crohn’s disease: application of EPACT criteria to the EC-IBD European Cohort. Gastroenterology 2006;130:A661–A662.
    External Resources
  50. Juillerat P, Pittet V, Mottet C, Felley C, Wietlisbach V, Gonvers JJ, Dubois RW, Vader JP, Burnard B, Froehlich F, Wolters F, Stockbruegger R, Michetti P: Appropriateness of initial treatment for mild-to-moderate luminal Crohn’s disease: application of EPACT criteria to the EC-IBD European cohort. Eur J Public Health 2006;16:98.
    External Resources

Article / Publication Details

First-Page Preview
Abstract of Paper

Published online: February 07, 2008
Issue release date: February 2008

Number of Print Pages: 8
Number of Figures: 1
Number of Tables: 5

ISSN: 0012-2823 (Print)
eISSN: 1421-9867 (Online)

For additional information: https://www.karger.com/DIG


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.